LAVA Therapeutics NV (LVTX)

LAVA Therapeutics NV Aktie (LVTX) Neueste Nachrichten

Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect? - Yahoo Singapore News

Yahoo Singapore News

How Much Of LAVA Therapeutics N.V. (NASDAQ:LVTX) Do Institutions Own? - Yahoo New Zealand News

Yahoo New Zealand News

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference - GlobeNewswire

GlobeNewswire

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference - Yahoo Finance

Yahoo Finance

LAVA Therapeutics Announces Progress and Stability - TipRanks.com - TipRanks

TipRanks

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results - GlobeNewswire

GlobeNewswire

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

GlobeNewswire Inc.

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA ... - GlobeNewswire

GlobeNewswire

LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Simply Wall St

Healthcare Stocks on the Move Thursday: LVTX, SCTL, ENVB, RNLX, KA, IRWD, AMPE, GRFS - InvestorsObserver

InvestorsObserver

LVTX Stock Quote Price and Forecast - CNN

CNN

Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results

Benzinga

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

GlobeNewswire Inc.

LAVA stock rises on clinical trial collaboration with Merck (NASDAQ:LVTX) - Seeking Alpha

Seeking Alpha

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results - Yahoo Finance

Yahoo Finance

Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall - Nasdaq

Nasdaq

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway - GlobeNewswire

GlobeNewswire

LAVA Therapeutics Announces Initial Data from Ongoing Phase 1/2a Trial of LAVA-1207 - Investing.com South Africa

Investing.com South Africa

Dec. 12 Quick Takes: Setbacks at ASH for Adicet and Lava - BioCentury

BioCentury

LAVA Therapeutics: Assessing A Promising Innovator (NASDAQ:LVTX) - Seeking Alpha

Seeking Alpha

Seagen and Lava enter license agreement for γδ bispecific T-cell engager LAVA-1223 - BioWorld Online

BioWorld Online

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a ... - Business Wire

Business Wire

LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022 - GlobeNewswire

GlobeNewswire

LAVA Therapeutics Expands Management Team with Three Key Appointments - GlobeNewswire

GlobeNewswire

Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager ... - Business Wire

Business Wire